GleamWall
中文EN

NVAX NOVAVAX INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1000694 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-61.3%
TTM net income YoY-122.5%
TTM EPS YoY-125.9%
Revenue 3-yr CAGR-26.8%
Net income 3-yr CAGR—

Margins

Gross margin78.0%
Operating margin-21.2%
Net margin-18.6%
FCF margin-59.2%
EBITDA margin-17.7%

Returns

ROE—
ROA-7.4%
ROIC (approx.)—
Asset turnover0.40x

Leverage & solvency

Liabilities / assets124.4%
Debt / equity—
Current ratio2.15x
Interest coverage-4.01x

Cash quality & payout

Operating cash flow / net income3.11x
Accruals ratio15.7%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$68.30M$56.70M$139.51M$147.14M$70.44M$239.24M$666.65M$88.31M
Cost of revenue$23.49M$14.25M$30.70M$22.10M$21.50M$15.32M$14.12M$36.67M
Gross profit$44.81M$42.45M$108.82M$125.03M$48.95M$223.91M$652.54M$51.64M
R&D expense$52.45M$70.69M$95.47M$75.88M$98.27M$79.23M$88.94M$104.38M
SG&A expense$23.64M$26.66M$28.78M$34.12M$31.66M$43.61M$48.09M$78.34M
Operating income-$31.28M-$54.91M-$15.43M$14.23M-$178.02M$101.07M$515.51M-$131.08M
Interest expense$5.40M$5.69M$4.90M$5.82M$5.48M$5.52M$5.72M$7.58M
Pretax income-$29.65M-$51.68M-$8.51M$17.90M-$203.04M$107.45M$519.85M-$73.58M
Income tax$1.72M$1.71M$985,000$376,000-$657,000$946,000$1.20M$7.45M
Net income-$31.38M-$53.39M-$9.49M$17.53M-$202.38M$106.51M$518.65M-$81.03M
EBITDA-$28.23M-$51.85M-$12.37M$19.74M-$171.43M$108.63M$523.85M-$119.06M
EPS (basic)-0.19-0.32-0.06—-1.250.663.22—
EPS (diluted)-0.19-0.32-0.06—-1.250.622.93—
Weighted avg. shares (diluted)164.92M164.57M163.28M—162.35M177.22M177.62M—
Balance sheet
Cash & equivalents$222.46M$191.46M$228.36M$240.63M$283.36M$268.98M$278.48M$545.29M
Short-term investments$399.91M$527.88M$561.97M$494.45M$494.87M$358.56M$468.14M$392.89M
Inventory$18.50M$10.01M$11.46M$11.54M$13.51M$10.24M$10.26M$8.75M
Current assets$707.96M$771.10M$850.82M$978.28M$974.59M$919.51M$868.03M$1.13B
PP&E, net$36.28M$38.13M$42.15M$44.80M$49.12M$129.64M$133.54M$138.41M
Goodwill$112.08M$112.54M$112.89M$113.46M$113.08M$112.96M$112.03M$107.48M
Total assets$888.00M$955.58M$1.04B$1.18B$1.18B$1.34B$1.29B$1.56B
Current liabilities$329.85M$330.57M$342.46M$459.95M$429.87M$389.14M$422.17M$1.15B
Long-term debt$292.09M$291.49M$291.04M$244.21M————
Total debt$292.09M$291.49M$291.04M$244.21M————
Total liabilities$1.10B$1.15B$1.19B$1.30B$1.34B$1.30B$1.37B$2.18B
Shareholders' equity-$216.85M-$190.71M-$144.76M-$127.75M-$156.67M$37.62M-$75.64M-$623.84M
Net debt$69.63M$100.03M$62.68M$3.58M————
Shares outstanding164.99M164.82M164.42M162.58M162.47M162.16M161.96M160.42M
Cash flow statement
Operating cash flow-$94.24M-$72.81M-$32.42M-$39.48M$107.80M-$127.46M-$185.50M-$173.16M
Capital expenditure$1.02M$588,000$1.27M$2.08M$2.02M$527,000$1.59M$1.93M
Free cash flow-$95.26M-$73.39M-$33.69M-$41.55M$105.79M-$127.99M-$187.10M-$175.09M
Investing cash flow$127.78M$34.90M-$28.36M$20.48M-$136.53M$111.10M-$73.32M$144.01M
Financing cash flow-$2.00M$1.20M$37.67M-$6.60M$42.44M-$1.04M-$7.06M-$3.42M
Depreciation & amortization$3.05M$3.06M$3.06M$5.51M$6.58M$7.56M$8.34M$12.02M
Stock-based compensation$7.96M$8.09M$7.72M$7.97M$8.55M$9.21M$10.29M$10.45M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.